Publications in collaboration with researchers from Hospital Universitari Germans Trias i Pujol (12)

2018

  1. SEOM clinical guideline on unknown primary cancer (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 89-96

2011

  1. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: Efficacy and cardiac safety from the GEICAM/2004-05 study

    Annals of Oncology, Vol. 22, Núm. 12, pp. 2591-2596

2010

  1. Maintenance treatment with Pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001-01 study

    Breast Cancer Research and Treatment, Vol. 122, Núm. 1, pp. 169-176

2006

  1. Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: A GEIS study

    British Journal of Cancer, Vol. 94, Núm. 12, pp. 1797-1802

2005

  1. Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS)

    Sarcoma, Vol. 9, Núm. 3-4, pp. 127-132

  2. Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: A GEICO (Grupo Español de Investigación en Cáncer de Ovario) study

    Annals of Oncology, Vol. 16, Núm. 5, pp. 749-755

2004

  1. Salvage surgical resection after High-Dose Ifosfamide (HDIF) based regimens in Advanced Soft Tissue Sarcoma (ASTS): A potential positive selection bias - A study of the Spanish group for research on sarcomas (GEIS)

    Journal of Surgical Oncology, Vol. 88, Núm. 1, pp. 44-49

  2. Sequential Dose-Dense Doxorubicin and Ifosfamide for Advanced Soft Tissue Sarcomas: A Phase II Trial by the Spanish Group for Research on Sarcomas (GEIS)

    Cancer, Vol. 100, Núm. 7, pp. 1498-1506

2000

  1. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

    Clinical Cancer Research, Vol. 6, Núm. 6, pp. 2356-2362

  2. Doxorubicin and paclitaxel in advanced breast carcinoma: Importance of prior adjuvant anthracycline therapy

    Cancer, Vol. 89, Núm. 11, pp. 2169-2175

1997

  1. Combination of oral idarubicin and prednimustine in advanced breast cancer: A phase II study

    European Journal of Cancer Part A, Vol. 33, Núm. 2, pp. 312-315

1996

  1. Phase II study of mitonafide in non-small cell lung cancer (NSCLC)

    Investigational New Drugs, Vol. 14, Núm. 4, pp. 415-417